When Sean Duffy co-founded Omada Health in 2011, the pursuit was to reinvent how people manage chronic disease.
By 2015, Omada earned full recognition from the U.S. Centers for Disease Control & Prevention for company’s digital diabetes prevention program and in 2018 it began a clinical trial demonstrating more than 4% percent average weight loss in a year among users.
Health Evolution interviewed Duffy about the inspiration behind Omada Health, what perspective clients should expect in the next 18 months, and the most difficult challenge he has overcome as a leader.
Read More: https://www.healthevolution.com/insider/innovator-ceo-profile-omada-healths-sean-duffy/
Via: Health Evolution
The FDA approved an expanded indication for a transcarotid stent system to include patients at standard risk for adverse events from carotid endarterectomy, according to a press release from Silk Road Medical.
Silk Road Medical’s Enroute TCAR System Approved for Expanded Indication of Standard-Risk Patients
Via: Endovascular Today
May 2, 2022—Silk Road Medical, Inc. announced that the FDA approved expanded indications for the company’s Enroute stent for transcarotid artery revascularization (TCAR) to include patients at standard risk for adverse events from carotid endarterectomy (CEA). Previously, the stent was approved for use only in patients with anatomic or physiologic criteria that put them at high risk of complications from more invasive surgical procedures.